Maheen Zahid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maheen Zahid has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Francis Asante Baadu
Internal Medicine, Komfo Anokye Teaching Hospital, Kumasi, GHA
2 shared publications- Ahmed Hazazi
Department of Public Health, College of Health Sciences, Saudi Electronic University, Riyadh 13316, Saudi Arabia
1 shared publication - Ahmed Raza
Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan
1 shared publication Asma Malik Sadaqat
Department of Obstetrics and Gynaecology, District Health Authority, Rawalpindi, PAK
1 shared publication- Aymar Akilimali
Faculty of Medicine University of Goma Goma DR Congo
1 shared publication - Babar Ali
University Institute of Radiological Sciences and Medical Imaging Technology, The University of Lahore, Lahore 54000, Pakistan
1 shared publication
Latest Publications
- 13 February 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (1) , 55
Mortality patterns in patients with chronic obstructive pulmonary disease and diabetes mellitus in the United States: a retrospective analysis from 1999 to 2019
Aims The global prevalence of DM and COPD is increasing. This study offers a longitudinal analysis of mortality patterns due to these two diseases along with regional and demographic insights that highlight disparities in mortality rates in the US from 1999 to 2019. Methods CDC WONDER database was used to determine crude mortality rates (CMR) and age-adjusted mortality rates (AAMRs) per 1,000,000 individuals, 25 years and above. Join point Regression was used to examine annual percent change (APC), average APC (AAPC) and parallelism. Results From 1999 to 2019, there were 613,779 deaths with an AAPC of 1.59%. Males (175.88) had higher AAMR than females (108.48). American Indians had highest AAMR (159.12) while non-Hispanic Asians experienced lowest (54.08). AAMRs varied by region (Midwest: 154.69, South: 143.88, West: 127.36, Northeast: 109.26). States with highest AAMR were West Virginia and Oklahoma; those with the lowest were Utah and Hawaii. Non-metropolitan areas showed higher mortality (184.02) than metropolitan areas (125.78). Crude mortality rate was highest for the 85 + age group. Conclusions The US saw an upward trend in mortality where both COPD and DM were documented on death certificates. These trends were more pronounced among males, American Indians, and the Midwestern region.
- 13 February 2026
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 25 (1) , 55
Mortality patterns in patients with chronic obstructive pulmonary disease and diabetes mellitus in the United States: a retrospective analysis from 1999 to 2019
Aims The global prevalence of DM and COPD is increasing. This study offers a longitudinal analysis of mortality patterns due to these two diseases along with regional and demographic insights that highlight disparities in mortality rates in the US from 1999 to 2019. Methods CDC WONDER database was used to determine crude mortality rates (CMR) and age-adjusted mortality rates (AAMRs) per 1,000,000 individuals, 25 years and above. Join point Regression was used to examine annual percent change (APC), average APC (AAPC) and parallelism. Results From 1999 to 2019, there were 613,779 deaths with an AAPC of 1.59%. Males (175.88) had higher AAMR than females (108.48). American Indians had highest AAMR (159.12) while non-Hispanic Asians experienced lowest (54.08). AAMRs varied by region (Midwest: 154.69, South: 143.88, West: 127.36, Northeast: 109.26). States with highest AAMR were West Virginia and Oklahoma; those with the lowest were Utah and Hawaii. Non-metropolitan areas showed higher mortality (184.02) than metropolitan areas (125.78). Crude mortality rate was highest for the 85 + age group. Conclusions The US saw an upward trend in mortality where both COPD and DM were documented on death certificates. These trends were more pronounced among males, American Indians, and the Midwestern region.
- Open Access
- 26 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e95469
Assessing Quality of Life and Patient-Reported Outcomes in Diabetic Macular Edema Treated With Anti-vascular Endothelial Growth Factor (Anti-VEGF) Agents: A Systematic Review and Meta-Analysis
Diabetic macular edema (DME) is a leading cause of vision impairment, with profound effects on patients’ quality of life (QoL). Anti-vascular endothelial growth factor (anti-VEGF) agents are the current standard of care, but their impact on patient-reported outcomes (PROMs) remains incompletely understood. We conducted a systematic review and meta-analysis of five randomized controlled trials (RCTs) and one cohort study involving 1,793 participants, evaluating the effects of anti-VEGF therapy compared with sham injections or laser therapy on QoL as measured by the National Eye Institute Visual Function Questionnaire (NEI VFQ-25). Pooled analysis demonstrated a statistically significant improvement in composite QoL scores with anti-VEGF therapy (mean difference 3.11; 95% CI 1.89-4.33; p<0.00001), although the absolute magnitude of improvement was modest. Subgroup analysis revealed greater benefit compared with sham injections than with laser therapy, and long-term follow-up (24 months) showed more pronounced gains compared with shorter durations. Sensitivity analysis excluding the non-randomized study confirmed the robustness of these findings. While anti-VEGF therapy improves QoL in patients with DME, real-world barriers such as treatment burden, access, and cost may limit patient-perceived benefits. Future research should integrate patient-centered approaches to better capture the treatment impact beyond visual outcomes.
- 26 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e95469
Open AccessAssessing Quality of Life and Patient-Reported Outcomes in Diabetic Macular Edema Treated With Anti-vascular Endothelial Growth Factor (Anti-VEGF) Agents: A Systematic Review and Meta-Analysis
Diabetic macular edema (DME) is a leading cause of vision impairment, with profound effects on patients’ quality of life (QoL). Anti-vascular endothelial growth factor (anti-VEGF) agents are the current standard of care, but their impact on patient-reported outcomes (PROMs) remains incompletely understood. We conducted a systematic review and meta-analysis of five randomized controlled trials (RCTs) and one cohort study involving 1,793 participants, evaluating the effects of anti-VEGF therapy compared with sham injections or laser therapy on QoL as measured by the National Eye Institute Visual Function Questionnaire (NEI VFQ-25). Pooled analysis demonstrated a statistically significant improvement in composite QoL scores with anti-VEGF therapy (mean difference 3.11; 95% CI 1.89-4.33; p<0.00001), although the absolute magnitude of improvement was modest. Subgroup analysis revealed greater benefit compared with sham injections than with laser therapy, and long-term follow-up (24 months) showed more pronounced gains compared with shorter durations. Sensitivity analysis excluding the non-randomized study confirmed the robustness of these findings. While anti-VEGF therapy improves QoL in patients with DME, real-world barriers such as treatment burden, access, and cost may limit patient-perceived benefits. Future research should integrate patient-centered approaches to better capture the treatment impact beyond visual outcomes.
- Open Access
- 3 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8)
Microbiome Imbalance and Pediatric Type 1 Diabetes Mellitus: An Updated Systematic Review of Gut Dysbiosis Evidence
Emerging evidence suggests that alterations in the gut microbiota may play a significant role in the development of type 1 diabetes mellitus (T1DM), particularly during childhood, when the immune and metabolic systems are still maturing. This systematic review aims to synthesize recent findings on the composition, diversity, and functional characteristics of gut microbiota in children with T1DM. A comprehensive literature search was conducted on PubMed, Cochrane Library, and Google Scholar for studies published between January 2019 and July 2025. Eligible studies included observational studies examining the gut microbiota in children with T1DM using validated sequencing methods. Six studies met the inclusion criteria and were analyzed for microbial composition, diversity, and associated immune and metabolic alterations. Most studies reported reduced microbial diversity and depletion of short-chain fatty acid (SCFA)-producing bacteria, such as Faecalibacterium and Roseburia, in T1DM children. An increased abundance of pro-inflammatory genera, including Bacteroides, Blautia, and Dorea, was frequently observed. Several studies have also identified elevated levels of gut permeability markers, such as zonulin and lipopolysaccharide (LPS), suggesting compromised intestinal barrier function. Notably, while some studies reported decreased abundance of Parasutterella in T1DM, one study observed its increased abundance, indicating regional or methodological variability. Gut dysbiosis, characterized by reduced diversity, loss of beneficial microbes, and increased intestinal permeability, is consistently associated with pediatric T1DM. However, the heterogeneity of specific taxa highlights the need for standardized longitudinal research. Understanding gut microbial alterations may provide novel opportunities for early intervention and disease modulation in at-risk children.
- 3 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8)
Open AccessMicrobiome Imbalance and Pediatric Type 1 Diabetes Mellitus: An Updated Systematic Review of Gut Dysbiosis Evidence
Emerging evidence suggests that alterations in the gut microbiota may play a significant role in the development of type 1 diabetes mellitus (T1DM), particularly during childhood, when the immune and metabolic systems are still maturing. This systematic review aims to synthesize recent findings on the composition, diversity, and functional characteristics of gut microbiota in children with T1DM. A comprehensive literature search was conducted on PubMed, Cochrane Library, and Google Scholar for studies published between January 2019 and July 2025. Eligible studies included observational studies examining the gut microbiota in children with T1DM using validated sequencing methods. Six studies met the inclusion criteria and were analyzed for microbial composition, diversity, and associated immune and metabolic alterations. Most studies reported reduced microbial diversity and depletion of short-chain fatty acid (SCFA)-producing bacteria, such as Faecalibacterium and Roseburia, in T1DM children. An increased abundance of pro-inflammatory genera, including Bacteroides, Blautia, and Dorea, was frequently observed. Several studies have also identified elevated levels of gut permeability markers, such as zonulin and lipopolysaccharide (LPS), suggesting compromised intestinal barrier function. Notably, while some studies reported decreased abundance of Parasutterella in T1DM, one study observed its increased abundance, indicating regional or methodological variability. Gut dysbiosis, characterized by reduced diversity, loss of beneficial microbes, and increased intestinal permeability, is consistently associated with pediatric T1DM. However, the heterogeneity of specific taxa highlights the need for standardized longitudinal research. Understanding gut microbial alterations may provide novel opportunities for early intervention and disease modulation in at-risk children.
- Open Access
- 24 June 2025
- Published by Springer Nature in Cureus
- Vol. 17 (6) , e86647
Diagnosing and Managing Trophoblastic Lesions in Cesarean Scars: A Systematic Review
Gestational trophoblastic disease (GTD) arises from an aberrant placenta and includes a spectrum of disorders ranging from premalignant to malignant. Changes in the epidemiology of GTD have been noted in various countries. Misdiagnosis can result in serious complications either because of the natural course of the disease or because of inadequate therapy that ensues. A systematic literature search was conducted in May 2025 using PubMed, Google Scholar, and the Cochrane Library. MeSH terms for "trophoblastic lesion" and "cesarean scar" were applied. Case reports describing trophoblastic disease in cesarean scars in women of any age were included. Non-trophoblastic lesions, cases not in cesarean scars, and non-English articles were excluded. Data were extracted from included studies and assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports. The review followed PRISMA guidelines. Thirty-six case reports from 2006 to 2024 were included. Patients ranged from 22 to 54 years and were multiparous with prior cesarean sections. Common symptoms included vaginal bleeding, amenorrhea, and pelvic pain. Serum β-hCG levels varied, with elevated levels in choriocarcinoma (CC) and normal or low levels in atypical placental site nodules (APSNs) and epithelioid trophoblastic tumors (ETTs). ETT was the most frequent lesion type, followed by CC and APSNs. Diagnosis used transvaginal ultrasonography (TVUS), Doppler imaging, and magnetic resonance imaging (MRI), confirmed by histopathology. Treatment was mainly surgical; chemotherapy was used in CC cases. Outcomes were favorable, with no recurrence in follow-up. Trophoblastic lesions in cesarean scars require heightened clinical awareness due to their diagnostic complexity. Early identification using imaging and histopathology is crucial. This review emphasizes standardized diagnostic pathways and the need for studies on management protocols.
- 24 June 2025
- Published by Springer Nature in Cureus
- Vol. 17 (6) , e86647
Open AccessDiagnosing and Managing Trophoblastic Lesions in Cesarean Scars: A Systematic Review
Gestational trophoblastic disease (GTD) arises from an aberrant placenta and includes a spectrum of disorders ranging from premalignant to malignant. Changes in the epidemiology of GTD have been noted in various countries. Misdiagnosis can result in serious complications either because of the natural course of the disease or because of inadequate therapy that ensues. A systematic literature search was conducted in May 2025 using PubMed, Google Scholar, and the Cochrane Library. MeSH terms for "trophoblastic lesion" and "cesarean scar" were applied. Case reports describing trophoblastic disease in cesarean scars in women of any age were included. Non-trophoblastic lesions, cases not in cesarean scars, and non-English articles were excluded. Data were extracted from included studies and assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports. The review followed PRISMA guidelines. Thirty-six case reports from 2006 to 2024 were included. Patients ranged from 22 to 54 years and were multiparous with prior cesarean sections. Common symptoms included vaginal bleeding, amenorrhea, and pelvic pain. Serum β-hCG levels varied, with elevated levels in choriocarcinoma (CC) and normal or low levels in atypical placental site nodules (APSNs) and epithelioid trophoblastic tumors (ETTs). ETT was the most frequent lesion type, followed by CC and APSNs. Diagnosis used transvaginal ultrasonography (TVUS), Doppler imaging, and magnetic resonance imaging (MRI), confirmed by histopathology. Treatment was mainly surgical; chemotherapy was used in CC cases. Outcomes were favorable, with no recurrence in follow-up. Trophoblastic lesions in cesarean scars require heightened clinical awareness due to their diagnostic complexity. Early identification using imaging and histopathology is crucial. This review emphasizes standardized diagnostic pathways and the need for studies on management protocols.